Fulcrum Therapeutics (FULC) Other Non-Current Liabilities (2018 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly Other Non-Current Liabilities of $197000.0 for Q2 2026, little changed year-over-year from $197000.0 in Q2 2025, and little changed quarter-over-quarter from $197000.0 in Q1 2026.
Powered by 
Analysis
Fulcrum Therapeutics (FULC) Other Non-Current Liabilities (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Other Non-Current Liabilities for 8 consecutive years, with $197000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Other Non-Current Liabilities changed 0.0% year-over-year to $197000.0; the TTM figure through Jun 2026 stood at $197000.0 (changed 0.0% YoY), while the FY2025 annual figure was $197000.0, changed 0.0% from the prior year.
- Other Non-Current Liabilities was little changed at $197000.0 in Q2 2026 per FULC's latest filing, from $197000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $447000.0 in Q2 2023 and bottomed at $197000.0 in Q2 2022.
- Historically, Other Non-Current Liabilities has averaged $218941.2 across 5 years, with a median of $197000.0 in 2022.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities surged 126.9% — and 2024, when it tumbled 55.93%.
- Fulcrum Therapeutics' Other Non-Current Liabilities stood at $197000.0 in 2022, then changed by 0.0% to $197000.0 in 2023, then changed by 0.0% to $197000.0 in 2024, then changed by 0.0% to $197000.0 in 2025, then changed by 0.0% to $197000.0 in 2026.
- Business Quant data shows FULC's Other Non-Current Liabilities at $197000.0 in Q2 2026, $197000.0 in Q1 2026, and $197000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Fulcrum Therapeutics | 293.24 Mn | 293.24 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 197,000.00 |
| Mar 31, 2026 | 197,000.00 |
| Dec 31, 2025 | 197,000.00 |
| Sep 30, 2025 | 197,000.00 |
| Jun 30, 2025 | 197,000.00 |
| Mar 31, 2025 | 197,000.00 |
| Dec 31, 2024 | 197,000.00 |
| Sep 30, 2024 | 197,000.00 |
| Jun 30, 2024 | 197,000.00 |
| Mar 31, 2024 | 197,000.00 |
| Dec 31, 2023 | 197,000.00 |
| Sep 30, 2023 | 197,000.00 |
| Jun 30, 2023 | 447,000.00 |
| Mar 31, 2023 | 320,000.00 |
| Dec 31, 2022 | 197,000.00 |
| Sep 30, 2022 | 197,000.00 |
| Jun 30, 2022 | 197,000.00 |
| Sep 30, 2020 | 7,000.00 |
| Jun 30, 2020 | 15,000.00 |
| Mar 31, 2020 | 31,000.00 |